| |
| |
|
| Insider
Information: |
Frates James M |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
318,827 |
|
|
Indirect Shares
|
184,010 |
|
|
| Direct
Value |
$2,148,775 |
|
|
|
Indirect Value
|
$3,642,655 |
|
|
| Total
Shares |
502,837 |
|
|
| Total
Value |
$5,791,430 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alkermes Plc |
ALKS |
SVP, Alks Inc; CFO ALKS |
2020-05-14 |
91,828 |
2020-05-14 |
155,669 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2021-06-16 |
1,035 |
2021-06-16 |
1,810 |
Premium* |
|
|
Amylyx Pharmaceuticals, Inc. |
AMLX |
|
2024-04-16 |
225,964 |
2024-04-16 |
26,531 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
262 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 7 of 11
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2015-11-24 |
4 |
OE |
$18.11 |
$99,994 |
D/D |
5,523 |
55,380 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• – – |
2012-02-21 |
4 |
AS |
$18.25 |
$91,274 |
D/D |
(5,000) |
79,625 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-12-31 |
4 |
AS |
$18.33 |
$68,760 |
D/D |
(3,752) |
92,207 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2013-12-16 |
4 |
OE |
$18.60 |
$473,128 |
D/D |
25,437 |
120,951 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2013-12-17 |
4 |
OE |
$18.60 |
$473,128 |
D/D |
25,437 |
115,951 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2024-03-05 |
4 |
S |
$18.73 |
$33,560 |
D/D |
(1,792) |
134,784 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-12-28 |
4 |
AS |
$18.76 |
$70,369 |
D/D |
(3,752) |
95,959 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• – – |
2012-02-01 |
4 |
AS |
$18.97 |
$189,687 |
D/D |
(10,000) |
79,625 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-11-28 |
4 |
AS |
$19.28 |
$103,395 |
D/D |
(5,364) |
99,711 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-11-18 |
4 |
D |
$19.49 |
$50,810 |
D/D |
(2,607) |
99,711 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-10-10 |
4 |
AS |
$19.56 |
$104,901 |
D/D |
(5,364) |
86,092 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-12-05 |
4 |
AS |
$19.64 |
$58,959 |
D/D |
(3,002) |
99,711 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-10-17 |
4 |
AS |
$19.83 |
$106,382 |
D/D |
(5,364) |
86,092 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-11-21 |
4 |
AS |
$19.84 |
$106,429 |
D/D |
(5,364) |
99,711 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-11-14 |
4 |
AS |
$20.15 |
$108,064 |
D/D |
(5,364) |
96,068 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-11-13 |
4 |
D |
$20.19 |
$151,425 |
D/D |
(7,500) |
96,068 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-02-21 |
4 |
D |
$20.24 |
$34,651 |
D/D |
(1,712) |
66,668 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-10-03 |
4 |
AS |
$20.64 |
$110,692 |
D/D |
(5,363) |
86,092 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2012-09-26 |
4 |
AS |
$20.65 |
$110,746 |
D/D |
(5,363) |
86,092 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-03-01 |
4 |
D |
$20.84 |
$27,571 |
D/D |
(1,323) |
69,845 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2013-02-14 |
4 |
AS |
$21.34 |
$186,754 |
D/D |
(8,750) |
92,207 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2013-01-16 |
4 |
AS |
$22.22 |
$194,435 |
D/D |
(8,750) |
92,207 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP & CFO, Alkermes plc |
• • – |
2013-03-14 |
4 |
AS |
$22.79 |
$358,991 |
D/D |
(15,750) |
92,207 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-05-16 |
4 |
AS |
$26.93 |
$875,451 |
D/D |
(32,500) |
55,676 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2019-08-15 |
4 |
OE |
$28.35 |
$226,800 |
D/D |
8,000 |
10,535 |
0 |
- |
|
262 Records found
|
|
Page 7 of 11 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
